This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Higher Order Structure 2018
Share |


Thank you to all who participated and helped make HOS 2018 a success!
We look forward to seeing you next year: April 8-10, 2019 in San Mateo, CA!

Protein higher order structure (HOS) includes the secondary, tertiary and quaternary structures of a protein, which comprise the three dimensional structures that are necessary for structure and function. Proteins in solution are dynamic molecules which can sample an ensemble of structures in solution, and have molecular properties which results in differing propensities to self associate and form a range of species from oligomers to visible particles. Changes in the HOS of proteins can  contribute to the quality attributes, and potentially safety, efficacy, and pharmacokinetic properties of protein therapeutica. Regulatory agencies require assessment of HOS to assess how protein structure is affected by manufacturing, storage and delivery; and analytical biosimilarity is an important part of evaluating potential changes in clinical safety and efficacy. There are many biophysical characterization methods and tools used in monitoring the attributes of protein therapeutics such as conformation and higher order structure.  However, since most biophysical analyses provide ensemble average structural information of the molecules, it is essential to evaluate if the observed changes are significant and are tracking changes in CQAs, and cannot be attributed to assay or process variability. Use of the appropriate biophysical method, method development and qualification to characterize the quality attributes at different stages of the product lifecycle are therefore a matter of interest and debate for a wide range of audiences. This Symposium will focus on various biophysical methods for assessment of protein HOS, as well as the applications of the appropriate tools during the different stages of protein therapeutic development and biosimilarity assessments, the theory and practice of biophysics, technical data from academia and industry as well as method qualification, validation and setting specifications.

Topics will include the following:

      • HOS in Discovery/Candidate Selection

      • HOS in Development

      • Biological Consequences of HOS

      • Established Methods and Fundamentals for HOS

      • Emerging Technology for HOS Evaluation

      • Young Scientist

      • HOS Biosimilarity and Comparability

      • Computational Methods for HOS

      • Late Breaking

    

We urge professionals from the following functions to not only attend but to fully engage in these important discussions: Discovery Sciences Process, Product Development Formulation Development Quality Assurance, Quality Control, Regulatory Affairs, Immunology Molecular, Biological Consequences, H/D Exchange and Cell Biology Analytical Development Manufacturing Sciences Clinical Pharmacology.

 

 

Want more information? Check out the "More in this Section" dropdown box at the top of the page!
Or contact CASSS at 510-428-0740 or info@casss.org


 
more Calendar

12/3/2018 » 12/4/2018
CMC Strategy Forum Japan 2018

1/28/2019 » 1/31/2019
CMC Strategy Forum and WCBP 2019

Membership Software Powered by YourMembership  ::  Legal